| Identification | Back Directory | [Name]
GSK2194069 | [CAS]
1332331-08-4 | [Synonyms]
GSK2194069
GSK2194069 >=97% (HPLC)
GSK2194069
(GSK 2194069
4-[4-(5-Benzofuranyl)phenyl]-5-[[(3S)-1-(cyclopropylcarbonyl)-3-pyrrolidinyl]methyl]-2,4-dihydro-3H-1,2,4-triazol-3-one
(S)-4-(4-(benzofuran-5-yl)phenyl)-5-((1-(cyclopropanecarbonyl)pyrrolidin-3-yl)methyl)-2,4-dihydro-3H-1,2,4-triazol-3-one
3H-1,2,4-Triazol-3-one, 4-[4-(5-benzofuranyl)phenyl]-5-[[(3S)-1-(cyclopropylcarbonyl)-3-pyrrolidinyl]methyl]-2,4-dihydro- | [Molecular Formula]
C25H24N4O3 | [MOL File]
1332331-08-4.mol | [Molecular Weight]
428.48 |
| Chemical Properties | Back Directory | [density ]
1.44±0.1 g/cm3(Predicted) | [storage temp. ]
2-8°C | [solubility ]
DMF:30.0(Max Conc. mg/mL);70.01(Max Conc. mM)
DMSO:54.28(Max Conc. mg/mL);126.68(Max Conc. mM)
Ethanol:4.91(Max Conc. mg/mL);11.46(Max Conc. mM) | [form ]
powder | [pka]
6.15±0.20(Predicted) | [color ]
white to light brown |
| Hazard Information | Back Directory | [Uses]
GSK 2194069 is a potent human fatty acid synthase (hFASN) inhibitor. | [Biochem/physiol Actions]
GSK2194069 is a fatty acid synthase (FAS) inhibitor. GSK2194069 is a potent and specific inhibitor of the β-ketoacyl reductase (KR) activity of hFAS with an IC50 of 7.7 ± 4.1 nM for the overall hFAS reaction. FAS is upregulated in some cancers, including prostate cancer. GSK2194069 was found to inhibit tumour growth in prostate cancer C42b cell xenografts generated in Nod-SCID-gamma mice. Cellular FAS inhibition reduced cell growth were also demonstrated in non-small-cell lung (A549) cancer cell lines with an average EC50 of 15 ± 0.5 nM. | [storage]
Store at +4°C |
|
| Company Name: |
Sigma-Aldrich
|
| Tel: |
021-61415566 800-8193336 |
| Website: |
https://www.sigmaaldrich.cn |
| Company Name: |
SPIRO PHARMA
|
| Tel: |
|
| Website: |
www.spiropharma.com.cn |
| Company Name: |
BOC Sciences
|
| Tel: |
16314854226 |
| Website: |
www.bocsci.com |
|